Developer docs
API playgroundTry for free, no card

Search company profiles

Aptevo Therapeutics

Full company profile

uuid00024z8

Namestring
Aptevo Therapeutics
Legal namestring
Aptevo Therapeutics Inc.
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company founded in 2016 and headquartered in Seattle, Washington. The company develops novel bispecific, multi-specific, and trispecific immunotherapies for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX antibody platforms. Both platforms are built on an IgG1 backbone and incorporate a unique, CRIS-7-derived anti-CD3 binding domain engineered to reduce cytokine release syndrome. The clinical pipeline is led by mipletamig (CD123 x CD3), in the RAINIER Phase 1b/2 trial for newly diagnosed acute myeloid leukemia, and ALG.APV-527 (4-1BB x 5T4), a Phase 1-ready solid-tumor candidate co-developed with Alligator Biosciences since 2017. Preclinical assets include APVO603 (4-1BB x OX40), APVO442 (PSMA x CD3), APVO711 (PD-L1 x CD40), and trispecific candidates APVO451, APVO452, and APVO455. In May 2026 the company expanded into radiopharmaceuticals via a 50/50 collaboration with Niowave to develop Actinium-225-based programs targeting Nectin-4 and other antigens.

Aptevo generates no product revenue and operates exclusively on a pre-commercial, partnership-driven business model. Management has stated that the company's platforms and clinical programs provide opportunities for broad partnering and licensing arrangements, including upfront fees, development milestones, and royalties. Operations are funded through repeated post-IPO equity issuances — including registered direct offerings, at-the-market offerings, and public offerings between 2023 and 2025 — supplemented by a $60 million equity line of credit from Yorkville Advisors secured in January 2026 that extends the cash runway into 2029. The company also received an initial 7.9% equity investment from Niowave in May 2026 in connection with the radiopharmaceutical collaboration.

The company is led by President and CEO Jeff Lamothe (effective April 1, 2026), Executive Chair and founding CEO Marvin L. White, SVP and CFO Daphne Taylor, SVP and CMO Dirk Huebner, SVP and CSO Mary J. Janatpour, and SVP and General Counsel SoYoung Kwon. Aptevo is listed on the Nasdaq Capital Market and implemented a 1-for-18 reverse stock split effective December 29, 2025 to maintain compliance with minimum bid price requirements. As of FY2025, the company reported a net loss of $26 million with zero revenue and is not yet profitable.

Short descriptiontext

Aptevo Therapeutics is a clinical-stage biotechnology company that develops proprietary bispecific and trispecific immunotherapies for cancer using its ADAPTIR and ADAPTIR-FLEX antibody platforms, with lead candidate mipletamig in a Phase 1b/2 trial for acute myeloid leukemia.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSeattle, United States
HQ citystring
Seattle
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody therapeutics, immuno-oncology drug development, clinical-stage biotechnology, trispecific antibody platform, hematology oncology pipeline
Industry3 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds524292
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Immuno-oncology bispecific antibody therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pre-revenue clinical-stage biotech
TypeLicensing Royalties
Description

Aptevo is a clinical-stage biotechnology company with no marketed products. The company reported $0 in revenue for the quarter ending September 30, 2025, and its current model is centered on advancing candidates through clinical development toward future out-licensing, partnership, and royalty arrangements.

aptevotherapeutics.com
2Future Out-licensing and Partnership Economics
TypeLicensing Royalties
Description

Management states the platforms and clinical programs "provide opportunities for a broad range of potential partnering and licensing arrangements, which may include upfront fees, development milestones, royalties and other compensation," indicating a planned future revenue mix based on license/collaboration upfronts, milestone payments, and royalties.

aptevotherapeutics.com
3Equity Capital Markets Financing
TypeTransaction Fee
Description

Operating cash is raised through repeat equity issuances including registered direct offerings, at-the-market offerings, public offerings, and an equity line of credit (e.g., $8M direct offering June 2025; $2.0M registered direct April 2025; $3.0M ATM Sept 2024; $2.75M financing July 2024; $4.6M public offering April 2024; $5M public offering Aug 2023; $60M equity line of credit from Yorkville Advisors Jan 2026).

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Not applicable — no marketed products; clinical-stage development only.
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Aptevo has no commercial product; future revenue is expected to come from licensing, milestones, and royalties.

aptevotherapeutics.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Aptevo Therapeutics is a clinical-stage biotechnology company that develops novel bispecific and trispecific immuno-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX antibody engineering platforms. Its pipeline targets hematologic malignancies (lead candidate Mipletamig for AML) and solid tumors (ALG.APV-527, APVO603, APVO442, APVO711, APVO451, APVO452, APVO455), with future revenue expected from out-licensing, milestone payments, and royalties rather than direct product sales.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 86–87% clinical benefit rate in frontline AML patients treated with mipletamig + venetoclax + azacitidine across 28–31 evaluable patients
+4 more records
Product overview1 text field

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company built on a platform-plus-modules architecture. Its two proprietary core platforms — ADAPTIR (modular bispecific antibody platform) and ADAPTIR-FLEX (heterodimer multi-specific platform) — produce a portfolio of named therapeutic candidates spanning hematologic malignancies and solid tumors. The clinical portfolio includes lead candidate Mipletamig (CD123 x CD3) in the RAINIER Phase 1b/2 trial for frontline AML and ALG.APV-527 (4-1BB x 5T4) with Phase 1 enrollment complete; the preclinical portfolio includes APVO603 (4-1BB x OX40), APVO442 (PSMA x CD3), APVO711 (PD-L1 x CD40), APVO451, APVO452, and APVO455. In 2026, Aptevo expanded into radiopharmaceuticals via a 50/50 collaboration with Niowave (Nectin-4 programs) and secured a $60 million equity line of credit to fund operations through 2029.

Product and service10 records
1ADAPTIR Bispecific Antibody Platform
CategoryCore platform technology
Description

Proprietary modular bispecific antibody platform technology that supports development of novel immuno-oncology therapeutics. Produces bispecific molecules with antibody-like half-life, stability, and manufacturability, and includes a unique anti-CD3 binding domain designed to reduce cytokine release. Used to design therapeutics with multiple mechanisms of action including redirected T cell cytotoxicity (RTCC), T cell co-stimulation, and immune checkpoint blockade.

2ADAPTIR-FLEX Heterodimer Multi-Specific Platform
CategoryCore platform technology
Description

Proprietary heterodimer platform technology built on an IgG1 Fc with 'knob in hole' assembly, enabling design of bispecific and multi-specific antibody candidates that can bind, activate, or block up to four different targets. Shares the IgG1 backbone, Fc mutations, and linkers with ADAPTIR and supports engineering of multi-specific candidates incorporating scFv, ECD, and cytokines.

3Mipletamig (APVO436)
CategoryLead clinical candidate (bispecific antibody)
Description

First-in-class CD123 x CD3 bispecific ADAPTIR molecule in a multi-center Phase 1b/2 RAINIER trial for newly diagnosed acute myeloid leukemia (AML) patients who are not candidates for intensive chemotherapy. Designed with a CRIS-7-derived CD3 binding domain to reduce cytokine release syndrome. Combined with venetoclax and azacitidine backbone, it has shown an 86-87% clinical benefit rate, 81% CR/CRi remission rate, and no CRS across 28-31 evaluable patients. Has received orphan drug designation for AML under the Orphan Drug Act.

4ALG.APV-527
CategoryClinical candidate (bispecific antibody)
Description

Bispecific 4-1BB x 5T4 antibody designed for tumor-directed treatment of solid tumors expressing the tumor-associated antigen 5T4. Built on Aptevo's ADAPTIR platform with binding domains from Alligator Biosciences' ALLIGATOR-GOLD human scFv library under a 2017 collaboration. Enrollment is complete in a multi-center, multi-cohort Phase 1 trial that showed positive safety/tolerability, 56% stable disease rate in efficacy-evaluable patients, and biological activity confirmation.

5APVO603
CategoryPreclinical candidate (bispecific antibody)
Description

Dual agonist bispecific antibody simultaneously targeting 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family, designed to deliver synergistic T cell co-stimulation for treatment of multiple solid tumor types. Includes an Fc that does not interact with Fc gamma receptors to reduce toxicity versus first-generation monospecific 4-1BB antibodies. Status: ongoing IND studies.

6APVO442
CategoryPreclinical candidate (multi-specific antibody)
Description

PSMA x CD3 multi-specific candidate built on Aptevo's ADAPTIR-FLEX platform for the treatment of prostate cancer. Engineered with high-affinity bivalent anti-PSMA binding and low-affinity monovalent CD3 binding to bias bio-distribution to the tumor and reduce peripheral T cell binding and cytokine release. Status: preclinical development.

7APVO711
CategoryPreclinical candidate (bispecific antibody)
Description

PD-L1 x CD40 dual mechanism bispecific antibody designed as a potential novel checkpoint molecule. Mechanism: blocks the PD-1/PD-L1 pathway and activates antigen presenting cells via CD40 crosslinking only when bound to PD-L1, intended to provide synergistic co-stimulation with reduced systemic toxicity compared to first-generation CD40 monoclonal antibodies. Status: preclinical studies.

8APVO451
CategoryPreclinical candidate (trispecific antibody)
Description

Aptevo's first trispecific antibody candidate that combines APC costimulation with a CD3 T cell engager targeting the tumor-associated antigen Nectin-4 on various solid tumors. Preclinical data demonstrating immune activation in hard-to-treat solid tumors (urothelial, breast, pancreatic) was debuted at the SITC Annual Meeting in November 2025.

9APVO452
CategoryPreclinical candidate (trispecific antibody)
Description

Trispecific antibody candidate combining APC costimulation with a CD3 T cell engager targeting the tumor-associated antigen PSMA. Part of Aptevo's expanding trispecific pipeline.

10APVO455
CategoryPreclinical candidate (bispecific antibody)
Description

Low-affinity CD3 T cell engager targeting the tumor-associated antigen PSMA on prostate cancer. Designed to reduce peripheral T cell binding and cytokine release while maintaining tumor-killing potency.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies and immuno-oncology therapeutics (e.g., MARGENZA, flotetuzumab-class programs). Closely comparable platform-plus-pipeline model targeting hematologic and solid tumors with similar bispecific DART architecture.

TypeBroad incumbent
Description

Established bispecific antibody company (DuoBody platform) with approved products (Epkinly/AbbVie, Rybrevant/Janssen). Comparable in targeting CD3-engager and immuno-oncology bispecific modalities, but at much larger commercial scale with validated platform deals.

TypeDirect peer
Description

Clinical-stage biotech building Probody and other masked/conditional-activation antibody platforms for oncology. Comparable in being a clinical-stage platform company with multiple partnered programs (e.g., with Astellas, BMS) targeting immuno-oncology.

TypeDirect peer
Description

Clinical-stage biotech with proprietary bispecific/multispecific antibody platforms (Azymetric, EFECT) used to develop oncology candidates including zanidatamab. Directly comparable platform-plus-multiple-candidates business model targeting HER2 and other oncology antigens.

TypeDirect peer
Description

Clinical-stage biotech developing precision bispecific antibodies (POWER and SAFE platforms) for oncology. Comparable in platform-based pipeline targeting immuno-oncology with multiple preclinical/clinical candidates, partnered with Sanofi and Exelixis.

TypeDirect peer
Description

Swedish clinical-stage biotech and Aptevo's existing co-development partner on ALG.APV-527. Comparable in developing bispecific antibodies for oncology (4-1BB class) with a similar clinical-stage, partnering-driven business model.

TypeDirect peer
Description

Clinical-stage biotech (acquired by Merck in 2024) developing T-cell engagers and bispecifics (HpnADS, TriTAC platforms) for oncology. Directly comparable T-cell engager platform business model, with Harpoon serving as a benchmark exit valuation reference for Aptevo.

TypeBroad incumbent
Description

Large-cap biopharma with the leading approved CD3 bispecific Blincyto (CD19×CD3) and a deep bispecific/immuno-oncology pipeline (BiTE platform). Comparable as a CD3-engager benchmark and potential licensing/partnering counterparty for Aptevo's CD123 and PSMA programs.

TypeBroad incumbent
Description

Global biopharma with multiple approved bispecific antibodies (Hemlibra, Vabysmo, Columvi) and broad oncology pipeline including CD3 engagers and 4-1BB programs. Comparable as a likely out-licensing partner and a benchmark for clinical/regulatory bispecific scale.

TypeBroad incumbent
Description

Global biopharma with leading PD-L1 inhibitor Imfinzi and active development of bispecific antibodies (e.g., datopotamab deruxtecan, multiple T-cell engagers). Comparable as a likely large-pharma counterparty for Aptevo's PD-L1×CD40 (APVO711) program and broader pipeline.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aptevo Therapeutics

Immuno-oncology bispecific antibody therapeuticsaptevotherapeutics.com

Aptevo Therapeutics is a clinical-stage biotechnology company that develops proprietary bispecific and trispecific immunotherapies for cancer using its ADAPTIR and ADAPTIR-FLEX antibody platforms, with lead candidate mipletamig in a Phase 1b/2 trial for acute myeloid leukemia.

What Aptevo Therapeutics does

Aptevo Therapeutics Inc. (NASDAQ: APVO) is a clinical-stage biotechnology company founded in 2016 and headquartered in Seattle, Washington. The company develops novel bispecific, multi-specific, and trispecific immunotherapies for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX antibody platforms. Both platforms are built on an IgG1 backbone and incorporate a unique, CRIS-7-derived anti-CD3 binding domain engineered to reduce cytokine release syndrome. The clinical pipeline is led by mipletamig (CD123 x CD3), in the RAINIER Phase 1b/2 trial for newly diagnosed acute myeloid leukemia, and ALG.APV-527 (4-1BB x 5T4), a Phase 1-ready solid-tumor candidate co-developed with Alligator Biosciences since 2017. Preclinical assets include APVO603 (4-1BB x OX40), APVO442 (PSMA x CD3), APVO711 (PD-L1 x CD40), and trispecific candidates APVO451, APVO452, and APVO455. In May 2026 the company expanded into radiopharmaceuticals via a 50/50 collaboration with Niowave to develop Actinium-225-based programs targeting Nectin-4 and other antigens.

Aptevo generates no product revenue and operates exclusively on a pre-commercial, partnership-driven business model. Management has stated that the company's platforms and clinical programs provide opportunities for broad partnering and licensing arrangements, including upfront fees, development milestones, and royalties. Operations are funded through repeated post-IPO equity issuances — including registered direct offerings, at-the-market offerings, and public offerings between 2023 and 2025 — supplemented by a $60 million equity line of credit from Yorkville Advisors secured in January 2026 that extends the cash runway into 2029. The company also received an initial 7.9% equity investment from Niowave in May 2026 in connection with the radiopharmaceutical collaboration.

The company is led by President and CEO Jeff Lamothe (effective April 1, 2026), Executive Chair and founding CEO Marvin L. White, SVP and CFO Daphne Taylor, SVP and CMO Dirk Huebner, SVP and CSO Mary J. Janatpour, and SVP and General Counsel SoYoung Kwon. Aptevo is listed on the Nasdaq Capital Market and implemented a 1-for-18 reverse stock split effective December 29, 2025 to maintain compliance with minimum bid price requirements. As of FY2025, the company reported a net loss of $26 million with zero revenue and is not yet profitable.

Aptevo Therapeutics firmographics

Firmographics
Name
Aptevo Therapeutics
Legal name
Aptevo Therapeutics Inc.
Website
https://aptevotherapeutics.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Aptevo Therapeutics is a clinical-stage biotechnology company that develops proprietary bispecific and trispecific immunotherapies for cancer using its ADAPTIR and ADAPTIR-FLEX antibody platforms, with lead candidate mipletamig in a Phase 1b/2 trial for acute myeloid leukemia.
Ownership category
akta.pro rank

Aptevo Therapeutics industry classification

Industry
Product category
Immuno-oncology bispecific antibody therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds (524292)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Bispecific antibody therapeutics
  • Immuno-oncology drug development
  • Clinical-stage biotechnology
  • Trispecific antibody platform
  • Hematology oncology pipeline

Where Aptevo Therapeutics is headquartered

Location

Headquarters

HQ city
Seattle
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aptevo Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-revenue clinical-stage biotech: Aptevo is a clinical-stage biotechnology company with no marketed products. The company reported $0 in revenue for the quarter ending September 30, 2025, and its current model is centered on advancing candidates through clinical development toward future out-licensing, partnership, and royalty arrangements.
  2. Future Out-licensing and Partnership Economics: Management states the platforms and clinical programs "provide opportunities for a broad range of potential partnering and licensing arrangements, which may include upfront fees, development milestones, royalties and other compensation," indicating a planned future revenue mix based on license/collaboration upfronts, milestone payments, and royalties.
  3. Equity Capital Markets Financing: Operating cash is raised through repeat equity issuances including registered direct offerings, at-the-market offerings, public offerings, and an equity line of credit (e.g., $8M direct offering June 2025; $2.0M registered direct April 2025; $3.0M ATM Sept 2024; $2.75M financing July 2024; $4.6M public offering April 2024; $5M public offering Aug 2023; $60M equity line of credit from Yorkville Advisors Jan 2026).

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNot applicable — no marketed products; clinical-stage development only.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Aptevo Therapeutics product offering

Product offering

Core offering

Aptevo Therapeutics is a clinical-stage biotechnology company that develops novel bispecific and trispecific immuno-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX antibody engineering platforms. Its pipeline targets hematologic malignancies (lead candidate Mipletamig for AML) and solid tumors (ALG.APV-527, APVO603, APVO442, APVO711, APVO451, APVO452, APVO455), with future revenue expected from out-licensing, milestone payments, and royalties rather than direct product sales.

Product overview

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company built on a platform-plus-modules architecture. Its two proprietary core platforms — ADAPTIR (modular bispecific antibody platform) and ADAPTIR-FLEX (heterodimer multi-specific platform) — produce a portfolio of named therapeutic candidates spanning hematologic malignancies and solid tumors. The clinical portfolio includes lead candidate Mipletamig (CD123 x CD3) in the RAINIER Phase 1b/2 trial for frontline AML and ALG.APV-527 (4-1BB x 5T4) with Phase 1 enrollment complete; the preclinical portfolio includes APVO603 (4-1BB x OX40), APVO442 (PSMA x CD3), APVO711 (PD-L1 x CD40), APVO451, APVO452, and APVO455. In 2026, Aptevo expanded into radiopharmaceuticals via a 50/50 collaboration with Niowave (Nectin-4 programs) and secured a $60 million equity line of credit to fund operations through 2029.

Differentiator

Problem solved

Functional benefit

Products and services

  • ADAPTIR Bispecific Antibody Platform Proprietary modular bispecific antibody platform technology that supports development of novel immuno-oncology therapeutics. Produces bispecific molecules with antibody-like half-life, stability, and manufacturability, and includes a unique anti-CD3 binding domain designed to reduce cytokine release. Used to design therapeutics with multiple mechanisms of action including redirected T cell cytotoxicity (RTCC), T cell co-stimulation, and immune checkpoint blockade.
  • ADAPTIR-FLEX Heterodimer Multi-Specific Platform Proprietary heterodimer platform technology built on an IgG1 Fc with 'knob in hole' assembly, enabling design of bispecific and multi-specific antibody candidates that can bind, activate, or block up to four different targets. Shares the IgG1 backbone, Fc mutations, and linkers with ADAPTIR and supports engineering of multi-specific candidates incorporating scFv, ECD, and cytokines.
  • Mipletamig (APVO436) First-in-class CD123 x CD3 bispecific ADAPTIR molecule in a multi-center Phase 1b/2 RAINIER trial for newly diagnosed acute myeloid leukemia (AML) patients who are not candidates for intensive chemotherapy. Designed with a CRIS-7-derived CD3 binding domain to reduce cytokine release syndrome. Combined with venetoclax and azacitidine backbone, it has shown an 86-87% clinical benefit rate, 81% CR/CRi remission rate, and no CRS across 28-31 evaluable patients. Has received orphan drug designation for AML under the Orphan Drug Act.
  • ALG.APV-527 Bispecific 4-1BB x 5T4 antibody designed for tumor-directed treatment of solid tumors expressing the tumor-associated antigen 5T4. Built on Aptevo's ADAPTIR platform with binding domains from Alligator Biosciences' ALLIGATOR-GOLD human scFv library under a 2017 collaboration. Enrollment is complete in a multi-center, multi-cohort Phase 1 trial that showed positive safety/tolerability, 56% stable disease rate in efficacy-evaluable patients, and biological activity confirmation.
  • APVO603 Dual agonist bispecific antibody simultaneously targeting 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family, designed to deliver synergistic T cell co-stimulation for treatment of multiple solid tumor types. Includes an Fc that does not interact with Fc gamma receptors to reduce toxicity versus first-generation monospecific 4-1BB antibodies. Status: ongoing IND studies.
  • APVO442 PSMA x CD3 multi-specific candidate built on Aptevo's ADAPTIR-FLEX platform for the treatment of prostate cancer. Engineered with high-affinity bivalent anti-PSMA binding and low-affinity monovalent CD3 binding to bias bio-distribution to the tumor and reduce peripheral T cell binding and cytokine release. Status: preclinical development.
  • APVO711 PD-L1 x CD40 dual mechanism bispecific antibody designed as a potential novel checkpoint molecule. Mechanism: blocks the PD-1/PD-L1 pathway and activates antigen presenting cells via CD40 crosslinking only when bound to PD-L1, intended to provide synergistic co-stimulation with reduced systemic toxicity compared to first-generation CD40 monoclonal antibodies. Status: preclinical studies.
  • APVO451 Aptevo's first trispecific antibody candidate that combines APC costimulation with a CD3 T cell engager targeting the tumor-associated antigen Nectin-4 on various solid tumors. Preclinical data demonstrating immune activation in hard-to-treat solid tumors (urothelial, breast, pancreatic) was debuted at the SITC Annual Meeting in November 2025.
  • APVO452 Trispecific antibody candidate combining APC costimulation with a CD3 T cell engager targeting the tumor-associated antigen PSMA. Part of Aptevo's expanding trispecific pipeline.
  • APVO455 Low-affinity CD3 T cell engager targeting the tumor-associated antigen PSMA on prostate cancer. Designed to reduce peripheral T cell binding and cytokine release while maintaining tumor-killing potency.

Quantifiable outcome

  • 86–87% clinical benefit rate in frontline AML patients treated with mipletamig + venetoclax + azacitidine across 28–31 evaluable patients
  • +4 more outcomes

Companies that use Aptevo Therapeutics

Customer profile

Ideal customer profiles2 records

Aptevo Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Aptevo Therapeutics partnerships and signals

Strategic signal

Scale indicators13 records

Recent moves6 records

Expansion highlights6 records

Aptevo Therapeutics competitors and assessment

Company assessment

Direct peers

  • MacroGenics: Clinical-stage biotech developing bispecific antibodies and immuno-oncology therapeutics (e.g., MARGENZA, flotetuzumab-class programs). Closely comparable platform-plus-pipeline model targeting hematologic and solid tumors with similar bispecific DART architecture.
  • CytomX Therapeutics: Clinical-stage biotech building Probody and other masked/conditional-activation antibody platforms for oncology. Comparable in being a clinical-stage platform company with multiple partnered programs (e.g., with Astellas, BMS) targeting immuno-oncology.
  • Zymeworks: Clinical-stage biotech with proprietary bispecific/multispecific antibody platforms (Azymetric, EFECT) used to develop oncology candidates including zanidatamab. Directly comparable platform-plus-multiple-candidates business model targeting HER2 and other oncology antigens.
  • Adagene: Clinical-stage biotech developing precision bispecific antibodies (POWER and SAFE platforms) for oncology. Comparable in platform-based pipeline targeting immuno-oncology with multiple preclinical/clinical candidates, partnered with Sanofi and Exelixis.
  • Alligator Bioscience: Swedish clinical-stage biotech and Aptevo's existing co-development partner on ALG.APV-527. Comparable in developing bispecific antibodies for oncology (4-1BB class) with a similar clinical-stage, partnering-driven business model.
  • Harpoon Therapeutics: Clinical-stage biotech (acquired by Merck in 2024) developing T-cell engagers and bispecifics (HpnADS, TriTAC platforms) for oncology. Directly comparable T-cell engager platform business model, with Harpoon serving as a benchmark exit valuation reference for Aptevo.

Broad incumbents

  • Genmab: Established bispecific antibody company (DuoBody platform) with approved products (Epkinly/AbbVie, Rybrevant/Janssen). Comparable in targeting CD3-engager and immuno-oncology bispecific modalities, but at much larger commercial scale with validated platform deals.
  • Amgen: Large-cap biopharma with the leading approved CD3 bispecific Blincyto (CD19×CD3) and a deep bispecific/immuno-oncology pipeline (BiTE platform). Comparable as a CD3-engager benchmark and potential licensing/partnering counterparty for Aptevo's CD123 and PSMA programs.
  • Roche: Global biopharma with multiple approved bispecific antibodies (Hemlibra, Vabysmo, Columvi) and broad oncology pipeline including CD3 engagers and 4-1BB programs. Comparable as a likely out-licensing partner and a benchmark for clinical/regulatory bispecific scale.
  • AstraZeneca: Global biopharma with leading PD-L1 inhibitor Imfinzi and active development of bispecific antibodies (e.g., datopotamab deruxtecan, multiple T-cell engagers). Comparable as a likely large-pharma counterparty for Aptevo's PD-L1×CD40 (APVO711) program and broader pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Aptevo Therapeutics social profiles

Digital presence

Aptevo Therapeutics compliance and trust

Trust signal

Compliance4 records

Aptevo Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aptevo Therapeutics leadership team

Management profile

Number of profiles

Profiles12 records

Aptevo Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Aptevo Therapeutics funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aptevo Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptevo Therapeutics

What does Aptevo Therapeutics do?

Aptevo Therapeutics is a clinical-stage biotechnology company that develops novel bispecific and trispecific immuno-oncology therapeutics for cancer using its proprietary ADAPTIR and ADAPTIR-FLEX antibody engineering platforms. Its pipeline targets hematologic malignancies (lead candidate Mipletamig for AML) and solid tumors (ALG.APV-527, APVO603, APVO442, APVO711, APVO451, APVO452, APVO455), with future revenue expected from out-licensing, milestone payments, and royalties rather than direct product sales.

Is Aptevo Therapeutics a public or private company?

Aptevo Therapeutics is a public company. It is classified as public and is currently operating.

When was Aptevo Therapeutics founded?

Aptevo Therapeutics was founded in 2016. It employs 51 to 100 people.

Where is Aptevo Therapeutics based?

Aptevo Therapeutics is headquartered in Seattle, United States, in the North America region.

How does Aptevo Therapeutics make money?

Three revenue lines are on record. Pre-revenue clinical-stage biotech is the primary driver. The others are future Out-licensing and Partnership Economics and equity Capital Markets Financing.

Who are Aptevo Therapeutics's main competitors?

Direct peers on record are MacroGenics, CytomX Therapeutics, Zymeworks, Adagene, Alligator Bioscience and Harpoon Therapeutics. Broad incumbents are Genmab, Amgen, Roche and AstraZeneca.

Does Aptevo Therapeutics have an API?

No public API is recorded for Aptevo Therapeutics.

What industry is Aptevo Therapeutics in?

Aptevo Therapeutics's product category is Immuno-oncology bispecific antibody therapeutics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAptevo 3Q 2026: EPS ($5.19) — 10-Q SummaryAptevo reported a Q3 2026 net loss of $9.35 million, widening year over year, with diluted EPS of -$5.19. The loss was driven by a $2.8 million deemed dividend from the August warrant inducement, while R&D and G&A expenses declined. Mipletamig showed 79% of evaluable patients achieving CR/CRi, and phase 1b dose optimization is targeted for completion by year-end 2026.TradingViewAptevo Therapeutics Inc. (APVO) Reports 79% Remission Rate in TP53-Mutated AMLAptevo Therapeutics reported a 79% complete remission or complete remission with incomplete hematologic recovery rate among evaluable patients with TP53-mutated AML treated with mipletamig triplet, versus a published 41% benchmark. Ten of 47 patients receiving combination therapy advanced to stem cell transplantation.The future of tradingAptevo Therapeutics Raises $3 Million in Gross Proceeds From Warrant ExerciseAptevo Therapeutics closed an existing common warrants exercise, raising approximately $3 million in gross proceeds before fees. Holders exercised warrants for up to 2,777,778 shares at $1.08 per share, and new unregistered warrants cover up to 13,888,890 shares at the same price. The new warrants become exercisable upon stockholder approval and expire five years after initial exercise.Dealroom.coAptevo lines up $3M from warrant exercises — its second raise in three months | Dealroom NewsAptevo Therapeutics raised about $3 million from warrant exercises, with holders buying up to 2.78 million shares at $1.08 each. The company will issue new warrants for up to 13.89 million shares at the same price, creating dilution. Proceeds will fund working capital.The future of tradingAptevo Therapeutics Publishes Presentation on Tumor-Targeted CD40 ImmunotherapiesAptevo Therapeutics published a presentation on multispecific antibody-like molecules for solid tumors. In cell-culture studies, APVO451 and APVO452 showed greater tumor-cell killing than bispecific controls in an immunosuppressive microenvironment, and APVO451 stimulated exhausted T cells. APVO711 combined PD-L1 blockade with CD40 activation to enhance killing with T-cell engagers.TradingViewAptevo Therapeutics Reduces Mipletamig Infusion Reactions Ahead of Phase 2Aptevo Therapeutics reported substantially fewer infusion-related reactions after refining mipletamig's priming-dose regimen, advancing tolerability objectives for frontline AML. The regimen update supports Phase 2 preparations, with the company expecting to complete the RAINIER study by year-end 2026 and initiate Phase 2 in 2027.YahooAptevo Achieves Key Clinical Development Objective, Significantly Reducing Infusion-Related Reactions with Mipletamig in Frontline AMLAptevo Therapeutics announced a clinical milestone for mipletamig, a priming-dose regimen refinement that substantially reduced infusion-related reactions in frontline AML patients. The improvement builds on favorable safety data and supports Phase 2 development, with the RAINIER study expected to complete by year-end 2026.Stock TitanAptevo Mipletamig Trial Reports Fewer Infusion ReactionsAptevo Therapeutics announced that refinements to mipletamig's priming-dose regimen substantially reduced infusion-related reactions in frontline AML patients. The company expects to complete the RAINIER study by year-end 2026 and initiate Phase 2 development in 2027.The future of tradingAptevo Therapeutics Mipletamig Combination Enabled 21% Of Frontline Aml Patients To Advance To Stem Cell TransplantAptevo Therapeutics' SEC filing reports that its Mipletamig combination enabled 21% of frontline acute myeloid leukemia patients to advance to stem cell transplant. The company's Rainier trial is expected to conclude by year-end, with Phase 2 initiation anticipated in the first half of 2027.The future of tradingAptevo spotlights tumor-targeted CD40 multispecific program at SITC 2026 meetingAptevo Therapeutics announced a presentation at the SITC 2026 Annual Meeting highlighting its CD40-directed multispecific cancer immunotherapy platform. The work targets solid tumors by concentrating immune activation in the tumor microenvironment to strengthen anti-tumor responses while limiting systemic activation. Results have not been presented yet; data are scheduled for November 4-8, 2026.